Verastem's low-stakes comeback gamble on an AbbVie/Infinity castoff pays off with positive CLL data
Verastem CEO $VSTM Robert Forrester was able to pick up the late-stage cancer drug duvelisib from a badly wounded Infinity Pharmaceuticals late last year for exactly nothing up front. And now he’s setting out to prove that the drug is a steal, offering up one incomplete but positive snapshot of top-line Phase III data to prove that he has a shot at a near-term approval that could be worth up to $300 million a year in the US market alone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
